Dyadic International (NASDAQ:DYAI) Shares Pass Below Fifty Day Moving Average – Here’s Why

Dyadic International Inc. (NASDAQ:DYAI)’s share price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.78 and traded as low as $0.7550. Dyadic International shares last traded at $0.8486, with a volume of 166,010 shares traded.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Dyadic International currently has a consensus rating of “Hold” and a consensus target price of $3.00.

Dyadic International Stock Up 8.9%

The firm has a market capitalization of $30.92 million, a price-to-earnings ratio of -3.69 and a beta of 1.17. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. The firm has a 50 day moving average price of $0.78 and a two-hundred day moving average price of $0.84.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. The firm had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. On average, equities analysts expect that Dyadic International Inc. will post 0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares during the last quarter. Marathon Capital Management raised its stake in Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 50,000 shares in the last quarter. Apis Capital Advisors LLC acquired a new stake in Dyadic International during the third quarter valued at approximately $1,817,000. Landscape Capital Management L.L.C. acquired a new stake in Dyadic International during the third quarter valued at approximately $190,000. Finally, Bank of America Corp DE raised its stake in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares in the last quarter. Hedge funds and other institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.